Equity (Tables)

3 Months Ended

Mar. 31, 2023

Stockholders Equity Note [Abstract]

Summary of the Warrants

As of March 31, 2023, the Company had 43,590,201 outstanding warrants to purchase Class A common stock. A summary of the warrants is as follows:

	Number of shares		Exercise price			Expiration date
Dragasac Warrant		6,529,818	$	6.77	*	March 16, 2025
Public Warrants		14,374,488	$	11.50		July 16, 2026
Sponsor Warrants		8,499,999	$	11.50		July 16, 2026
May 2022 PIPE Warrants		4,054,055	$	8.25	**	May 20, 2027
March 2023 PIPE Warrants		9,381,841	$	3.00		March 27, 2028
March 2023 Loan Warrants		750,000	$	0.71		March 17, 2028
		43,590,201

* The exercise price is the lessor of $6.77 per share or 80% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii) the price at which one share of common stock is sold to the public market in an initial public offering.

** The exercise price was amended to $0.75 effective April 10, 2023 in connection with the registered direct offering. The expiration date was also amended to be five and one-half years following the closing of the offering or October 10, 2028. Refer to Note 16 for additional information regarding subsequent events.